Biomx Inc. stock surges amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 27 Jan 26
Source: Benzinga
Biomx Inc. shares are up 129.27% in pre-market trading, reaching a 20-day high.
The significant price increase comes amid positive market conditions, with the Nasdaq-100 and S&P 500 both showing gains of 0.54% and 0.25%, respectively. This surge in Biomx's stock price reflects a strong investor interest, likely driven by broader market trends.
Investors are optimistic about the company's future prospects, and the current market strength may further bolster confidence in Biomx's growth potential.
Analyst Views on PHGE
Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.580
Low
26.00
Averages
26.00
High
26.00
Current: 6.580
Low
26.00
Averages
26.00
High
26.00
About PHGE
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
